NBIX FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Neurocrine Biosciences in a note issued to investors on Friday, April 25th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $4.20 for the year, down from their previous estimate of $4.21. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Several other analysts have also weighed in on NBIX. Royal Bank of Canada upgraded Neurocrine Biosciences from a "sector perform" rating to an "outperform" rating and decreased their price target for the company from $138.00 to $137.00 in a report on Monday, April 14th. HC Wainwright lowered their target price on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Needham & Company LLC upgraded Neurocrine Biosciences from a "hold" rating to a "buy" rating and set a $138.00 price target on the stock in a research note on Tuesday, April 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective for the company. Finally, William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $161.14.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $106.73 on Monday. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98. The business's 50 day moving average is $107.16 and its two-hundred day moving average is $122.22. The stock has a market capitalization of $10.56 billion, a P/E ratio of 32.44, a PEG ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently made changes to their positions in NBIX. Virtu Financial LLC purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at approximately $1,985,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at approximately $384,000. Tidal Investments LLC raised its position in shares of Neurocrine Biosciences by 52.8% during the 3rd quarter. Tidal Investments LLC now owns 15,043 shares of the company's stock valued at $1,733,000 after buying an additional 5,197 shares during the period. Tri Ri Asset Management Corp purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at approximately $3,236,000. Finally, GAMMA Investing LLC raised its position in shares of Neurocrine Biosciences by 32.0% during the 4th quarter. GAMMA Investing LLC now owns 2,295 shares of the company's stock valued at $313,000 after buying an additional 557 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the transaction, the director now directly owns 521,618 shares of the company's stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kyle Gano sold 1,541 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67. Following the completion of the transaction, the chief executive officer now directly owns 136,778 shares in the company, valued at $20,909,252.86. This trade represents a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,801 shares of company stock worth $2,834,677. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences announced that its board has authorized a stock buyback plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.